SCHEMBL29640130

SCHEMBL29640130

NC(=O)N1CCc2nocc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.46
DPP4 P27487 4/20 0.39
DPP8 Q6V1X1 2/20 0.39
DPP7 Q9UHL4 2/20 0.39
HSD11B1 P28845 1/20 0.36
PTGS1 P23219 1/20 0.34
SYK P43405 1/20 0.34
TSHR P16473 2/20 0.33
NOTUM Q6P988 1/20 0.33
TMPRSS2 O15393 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAOA P21397 1/20 0.33
SLC6A2 P23975 1/20 0.33
RYR2 Q92736 1/20 0.33
HTT P42858 1/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301219 0.85 NAMPT (0.46) NAMPTDPP4DPP8DPP7HSD11B1
SCHEMBL31387247 0.76 ESR2 (0.53) NAMPTMAPT
SCHEMBL23779972 0.72 RYR2 (0.38) PTGS1TSHRNOTUMTMPRSS2HTR1A
SCHEMBL29838195 0.72 BRD4 (0.31) NAMPT
SCHEMBL30914558 0.71 PDE4D (0.41) NAMPTDPP4HSD11B1
SCHEMBL4753809 0.71 DPP8 (0.47) NAMPTDPP8TSHRNOTUMTMPRSS2
SCHEMBL30796134 0.71 HDAC1 (0.40) NAMPTMAPTHSP90AB1
SCHEMBL21500638 0.70 LMNA (0.39) NAMPTDPP4PTGS1TSHRLMNA
SCHEMBL25238835 0.70 GPR142 (0.58) TSHRTMPRSS2CYP2D6HTTLMNA
SCHEMBL546055 0.68 NOTUM (0.68) DPP8DPP7HSD11B1TSHRNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450271-B Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition 纽力克斯治疗公司 2024-09-20 CN disclosed
CN-114450271-A Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition 纽力克斯治疗公司 2022-05-06 CN disclosed
US-20220135590-A1 ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS Janssen Science Ireland Unlimited Company (IE) 2022-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135590-A1 ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS HAVCR2, XDH, PYGL NAMPT 357/4885DPP4 1138/4885DPP8 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.